Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

2026 data Public-data reference. official source

Coronary Heart Disease

Open-data reference.

20 US clinical trials · 3 currently recruiting

Active & Recent Trials

RECRUITING NA 500 participants

Project 3: ACHIEVE- CHD

University Hospitals Cleveland Medical Center

NCT05918380

RECRUITING NA 95 participants

Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients

West Virginia School of Osteopathic Medicine

NCT06049420

RECRUITING Early Phase 1 52 participants

Thiamine Intervention and Coronary Artery Bypass Grafting

University of California, Los Angeles

NCT06326996

COMPLETED Phase 3 15,871 participants

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Hoffmann-La Roche

NCT00658515

COMPLETED 4,350 participants

Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree

CardioDx

NCT00500617

COMPLETED Phase 3 1,743 participants

12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe

AstraZeneca

NCT00525824

COMPLETED Phase 3 1,445 participants

Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood

Abbott

NCT00300482

COMPLETED Phase 4 1,000 participants

Cholesterol and Pharmacogenetic Study

UCSF Benioff Children's Hospital Oakland

NCT00451828

COMPLETED Phase 3 682 participants

Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood

AbbVie (prior sponsor, Abbott)

NCT00616772

COMPLETED 581 participants

Coronary Obstruction Detection by Molecular Personalized Gene Expression (Corus CAD or ASGES)

CardioDx

NCT01117506

COMPLETED Phase 2 534 participants

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease

Daiichi Sankyo

NCT00185042

COMPLETED NA 489 participants

Heart to Health: A Combined Lifestyle and Medication Intervention to Reduce Cardiovascular Disease (CVD) Risk

University of North Carolina, Chapel Hill

NCT01245686

COMPLETED NA 361 participants

An IT Approach to Implementing Depression Treatment in Cardiac Patients (iHeart DepCare)

Columbia University

NCT03882411

COMPLETED NA 338 participants

Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids

Beth Israel Deaconess Medical Center

NCT01624727

COMPLETED Phase 2 130 participants

A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease

Hoffmann-La Roche

NCT00655473

COMPLETED Phase 2 31 participants

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Novartis Pharmaceuticals

NCT06097663

COMPLETED NA 26 participants

Walnut Consumption, Endothelial Function, and Biomarkers

Brigham and Women's Hospital

NCT01884363

COMPLETED NA 22 participants

Study of the Arachidonate 5-Lipoxygenase Enzyme in Affecting the Risk for Coronary Heart Disease

University of Florida

NCT00379808

COMPLETED NA 20 participants

Developing and Evaluating an Indoor Air Pollution Intervention Among Cardiovascular Patients: the AIRWISE Study

University of Montana

NCT06384625

COMPLETED NA 5 participants

Relationship Between the Menstrual Cycle and Heart Disease in Women

Oregon Health and Science University

NCT01546454

Phase Distribution

PhaseTrial count
Early Phase 1 1
Phase 2 3
Phase 3 4
Phase 4 1

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Coronary Heart Disease Trial Landscape

ClinicalTrials.gov lists 20 US studies indexed under Coronary Heart Disease, and 3 of those are currently open to recruitment — roughly 15% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

The phase distribution for Coronary Heart Disease shows 5 late-stage studies (Phase 3 and Phase 4 combined) alongside 4 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

Top sponsor activity for Coronary Heart Disease is led by CardioDx with 2 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 20 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Coronary Heart Disease?

PlainTrial tracks 20 US clinical trials for Coronary Heart Disease, of which 3 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Coronary Heart Disease?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →